Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2020

04.02.2020 | review

Evidence-based follow-up in patients with Hodgkin’s lymphoma and aggressive B-cell non-Hodgkin’s lymphoma

verfasst von: Dr. Thomas Spanberger

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

In both Hodgkin’s Lymphoma and aggressive Non-Hodgkin’s-Lymphoma, complete remissions and long term survival can be achieved in a high number of patients, especially in those young and fit for intensive chemotherapy. The purpose of this review is to summarize the evidence and recommended follow-up procedures following curative therapy for these entities. After completion of treatment, a tight follow-up schedule is recommended, with history and physical examination being the mainstay of follow-up. There is no convincing evidence of the value of routine imaging for follow-up of lymphoma.
After several years, the risk of recurrence decreases drastically, and the focus shifts to the detection and management of late treatment effects. One of the most significant late toxicities of lymphoma treatment is cardiac toxicity, both due to mediastinal/chest radiotherapy and cardiotoxic chemotherapy. Patients have to be watched closely, and other cardiac risk factors should be managed aggressively. While there is no randomized trial proving benefit, serial echocardiograms seem a reasonable approach to approach this high-risk population.
Secondary neoplasms after treatment are another focus of follow-up. Chemotherapy and radiotherapy have strong potential to lead to both leukemia and secondary lymphoma, as well as solid tumors such as lung cancer and gastrointestinal tumors. Radiation therapy greatly increases the risk for breast cancer. Young (<40 years) women receiving radiotherapy should, in follow-up after treatment, be screened for breast cancer. Other than this, there is currently no sufficient rationale for any deviation from the cancer screening recommendations for the general population.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol. 2007;25(23):3495–502. PubMed Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol. 2007;25(23):3495–502. PubMed
2.
Zurück zum Zitat von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30(9):907–13. von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30(9):907–13.
3.
Zurück zum Zitat Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348(24):2386–95. PubMed Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348(24):2386–95. PubMed
4.
Zurück zum Zitat Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: A randomised trial. Lancet. 2002;359(9323):2065–71. PubMed Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: A randomised trial. Lancet. 2002;359(9323):2065–71. PubMed
5.
Zurück zum Zitat Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62. PubMed Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62. PubMed
6.
Zurück zum Zitat Pfreundschuh M, Kuhnt E, Trümper L, Österborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6‑year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–22. PubMed Pfreundschuh M, Kuhnt E, Trümper L, Österborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6‑year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–22. PubMed
7.
Zurück zum Zitat Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42. PubMed Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42. PubMed
8.
Zurück zum Zitat Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B‑cell lymphoma: An open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13(12):1250–9. PubMed Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B‑cell lymphoma: An open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13(12):1250–9. PubMed
9.
Zurück zum Zitat Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B‑cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90. PubMedPubMedCentral Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B‑cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90. PubMedPubMedCentral
10.
Zurück zum Zitat Sussman J, Varela NP, Cheung M, Hicks L, Kraftcheck D, Mandel J, et al. Follow-up care for survivors of lymphoma who have received curative-intent treatment. Curr Oncol. 2016;23(5):e499–e513. PubMedPubMedCentral Sussman J, Varela NP, Cheung M, Hicks L, Kraftcheck D, Mandel J, et al. Follow-up care for survivors of lymphoma who have received curative-intent treatment. Curr Oncol. 2016;23(5):e499–e513. PubMedPubMedCentral
11.
Zurück zum Zitat Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv19–iv29. PubMed Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv19–iv29. PubMed
12.
Zurück zum Zitat Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B‑cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–v25. PubMed Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B‑cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–v25. PubMed
13.
Zurück zum Zitat Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol. 2014;32(27):3059–68. PubMed Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol. 2014;32(27):3059–68. PubMed
14.
Zurück zum Zitat Jakobsen LH, Hutchings M, de Nully Brown P, Linderoth J, Mylam KJ, Molin D, et al. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: A Danish-Swedish population-based observational study. Br J Haematol. 2016;173(2):236–44. PubMed Jakobsen LH, Hutchings M, de Nully Brown P, Linderoth J, Mylam KJ, Molin D, et al. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: A Danish-Swedish population-based observational study. Br J Haematol. 2016;173(2):236–44. PubMed
15.
Zurück zum Zitat Dann EJ, Berkahn L, Mashiach T, Frumer M, Agur A, McDiarmid B, et al. Hodgkin lymphoma patients in first remission: Routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass. Br J Haematol. 2014;164(5):694–700. PubMed Dann EJ, Berkahn L, Mashiach T, Frumer M, Agur A, McDiarmid B, et al. Hodgkin lymphoma patients in first remission: Routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass. Br J Haematol. 2014;164(5):694–700. PubMed
16.
Zurück zum Zitat El-Galaly TC, Jakobsen LH, Hutchings M, de Nully Brown P, Nilsson-Ehle H, Székely E, et al. Routine imaging for diffuse large B‑cell lymphoma in first complete remission does not improve post-treatment survival: A Danish-Swedish population-based study. J Clin Oncol. 2015;33(34):3993–8. PubMed El-Galaly TC, Jakobsen LH, Hutchings M, de Nully Brown P, Nilsson-Ehle H, Székely E, et al. Routine imaging for diffuse large B‑cell lymphoma in first complete remission does not improve post-treatment survival: A Danish-Swedish population-based study. J Clin Oncol. 2015;33(34):3993–8. PubMed
17.
Zurück zum Zitat Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol. 2011;90(2):165–71. PubMed Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol. 2011;90(2):165–71. PubMed
18.
Zurück zum Zitat Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: A retrospective analysis of a uniformly-treated patient population. Ann Oncol. 2006;17(6):909–13. PubMed Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: A retrospective analysis of a uniformly-treated patient population. Ann Oncol. 2006;17(6):909–13. PubMed
19.
Zurück zum Zitat Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, et al. Utility of routine post-therapy surveillance imaging in diffuse large B‑cell lymphoma. J Clin Oncol. 2014;32(31):3506–12. PubMed Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, et al. Utility of routine post-therapy surveillance imaging in diffuse large B‑cell lymphoma. J Clin Oncol. 2014;32(31):3506–12. PubMed
20.
Zurück zum Zitat Hong J, Kim JH, Lee KH, Ahn HK, Park S, Sym SJ, et al. Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B‑cell lymphoma. Leuk Lymphoma. 2014;55(10):2312–8. PubMed Hong J, Kim JH, Lee KH, Ahn HK, Park S, Sym SJ, et al. Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B‑cell lymphoma. Leuk Lymphoma. 2014;55(10):2312–8. PubMed
21.
Zurück zum Zitat Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, et al. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol. 2013;88(5):400–5. PubMed Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, et al. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol. 2013;88(5):400–5. PubMed
22.
Zurück zum Zitat Chien S‑H, Liu C‑J, Hu Y‑W, Hong Y‑C, Teng C‑J, Yeh C‑M, et al. Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: A nationwide population-based study. Int J Cancer. 2015;137(3):658–65. PubMed Chien S‑H, Liu C‑J, Hu Y‑W, Hong Y‑C, Teng C‑J, Yeh C‑M, et al. Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: A nationwide population-based study. Int J Cancer. 2015;137(3):658–65. PubMed
23.
Zurück zum Zitat Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, et al. The ASH Choosing Wisely® campaign: Five hematologic tests and treatments to question. Hematology Am Soc Hematol Educ Program. 2013;2013:9–14. PubMed Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, et al. The ASH Choosing Wisely® campaign: Five hematologic tests and treatments to question. Hematology Am Soc Hematol Educ Program. 2013;2013:9–14. PubMed
24.
Zurück zum Zitat van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, et al. Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257–65. PubMedPubMedCentral van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, et al. Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257–65. PubMedPubMedCentral
25.
Zurück zum Zitat Sawyer DB. Anthracyclines and heart failure. N Engl J Med. 2013;368(12):1154–6. PubMed Sawyer DB. Anthracyclines and heart failure. N Engl J Med. 2013;368(12):1154–6. PubMed
26.
Zurück zum Zitat Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911. PubMed Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911. PubMed
27.
Zurück zum Zitat Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii155–vii66. PubMed Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii155–vii66. PubMed
28.
Zurück zum Zitat Schaapveld M, Aleman BMP, van Eggermond AM, Janus CPM, Krol ADG, van der Maazen RWM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s Lymphoma. N Engl J Med. 2015;373(26):2499–511. PubMed Schaapveld M, Aleman BMP, van Eggermond AM, Janus CPM, Krol ADG, van der Maazen RWM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s Lymphoma. N Engl J Med. 2015;373(26):2499–511. PubMed
29.
Zurück zum Zitat Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Second cancer risk after chemotherapy for Hodgkin’s lymphoma: A collaborative British cohort study. J Clin Oncol. 2011;29(31):4096–104. PubMed Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Second cancer risk after chemotherapy for Hodgkin’s lymphoma: A collaborative British cohort study. J Clin Oncol. 2011;29(31):4096–104. PubMed
30.
Zurück zum Zitat Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, Sacchi S. Risk for second malignancies in non-Hodgkin’s lymphoma survivors: A meta-analysis. Ann Oncol. 2011;22(8):1845–58. PubMed Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, Sacchi S. Risk for second malignancies in non-Hodgkin’s lymphoma survivors: A meta-analysis. Ann Oncol. 2011;22(8):1845–58. PubMed
31.
Zurück zum Zitat Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: A report from the German Hodgkin Study Group. Blood. 2014;123(11):1658–64. PubMed Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: A report from the German Hodgkin Study Group. Blood. 2014;123(11):1658–64. PubMed
32.
Zurück zum Zitat Aleman BMP, Raemaekers JMM, Tirelli U, Bortolus R, van’t Veer MB, Lybeert MLM, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003;348(24):2396–406. PubMed Aleman BMP, Raemaekers JMM, Tirelli U, Bortolus R, van’t Veer MB, Lybeert MLM, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003;348(24):2396–406. PubMed
33.
Zurück zum Zitat Gangavarapu LS, Surapaneni R. Diffuse large B‑cell Lymphoma survivorship: Risk of second malignancies in long term survivors. Blood. 2015;126(23):3921. Gangavarapu LS, Surapaneni R. Diffuse large B‑cell Lymphoma survivorship: Risk of second malignancies in long term survivors. Blood. 2015;126(23):3921.
34.
Zurück zum Zitat de Bruin ML, Sparidans J, van’t Veer MB, Noordijk EM, Louwman MWJ, Zijlstra JM, et al. Breast cancer risk in female survivors of Hodgkin’s lymphoma: Lower risk after smaller radiation volumes. J Clin Oncol. 2009;27(26):4239–46. PubMed de Bruin ML, Sparidans J, van’t Veer MB, Noordijk EM, Louwman MWJ, Zijlstra JM, et al. Breast cancer risk in female survivors of Hodgkin’s lymphoma: Lower risk after smaller radiation volumes. J Clin Oncol. 2009;27(26):4239–46. PubMed
35.
Zurück zum Zitat Ng AK, Garber JE, Diller LR, Birdwell RL, Feng Y, Neuberg DS, et al. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol. 2013;31(18):2282–8. PubMed Ng AK, Garber JE, Diller LR, Birdwell RL, Feng Y, Neuberg DS, et al. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol. 2013;31(18):2282–8. PubMed
36.
Zurück zum Zitat Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin’s lymphoma: A systematic review. Lancet Oncol. 2005;6(10):773–9. PubMed Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin’s lymphoma: A systematic review. Lancet Oncol. 2005;6(10):773–9. PubMed
37.
Zurück zum Zitat Schoenfeld JD, Mauch PM, Das P, Silver B, Marcus KJ, Stevenson MA, et al. Lung malignancies after Hodgkin lymphoma: Disease characteristics, detection methods and clinical outcome. Ann Oncol. 2012;23(7):1813–8. PubMed Schoenfeld JD, Mauch PM, Das P, Silver B, Marcus KJ, Stevenson MA, et al. Lung malignancies after Hodgkin lymphoma: Disease characteristics, detection methods and clinical outcome. Ann Oncol. 2012;23(7):1813–8. PubMed
38.
Zurück zum Zitat Wattson DA, DiPiro PJ, Das P, Hodgson DC, Mauch PM, Ng AK. Low-dose chest CT for lung cancer screening among Hodgkin lymphoma survivors: A cost-effectiveness analysis. Int J Radiat Oncol Biol Phys. 2013;87(2):S180. Wattson DA, DiPiro PJ, Das P, Hodgson DC, Mauch PM, Ng AK. Low-dose chest CT for lung cancer screening among Hodgkin lymphoma survivors: A cost-effectiveness analysis. Int J Radiat Oncol Biol Phys. 2013;87(2):S180.
39.
Zurück zum Zitat van den Belt-Dusebout AW, Aleman BMP, Besseling G, de Bruin ML, Hauptmann M, van’t Veer MB, et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys. 2009;75(5):1420–9. PubMed van den Belt-Dusebout AW, Aleman BMP, Besseling G, de Bruin ML, Hauptmann M, van’t Veer MB, et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys. 2009;75(5):1420–9. PubMed
40.
Zurück zum Zitat Cella L, Conson M, Caterino M, de Rosa N, Liuzzi R, Picardi M, et al. Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1802–8. PubMed Cella L, Conson M, Caterino M, de Rosa N, Liuzzi R, Picardi M, et al. Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1802–8. PubMed
41.
Zurück zum Zitat Sieniawski M, Reineke T, Nogova L, Josting A, Pfistner B, Diehl V, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: A report of the German Hodgkin Study Group (GHSG). Blood. 2008;111(1):71–6. PubMed Sieniawski M, Reineke T, Nogova L, Josting A, Pfistner B, Diehl V, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: A report of the German Hodgkin Study Group (GHSG). Blood. 2008;111(1):71–6. PubMed
42.
Zurück zum Zitat Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, et al. Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2005;23(30):7555–64. PubMed Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, et al. Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2005;23(30):7555–64. PubMed
Metadaten
Titel
Evidence-based follow-up in patients with Hodgkin’s lymphoma and aggressive B-cell non-Hodgkin’s lymphoma
verfasst von
Dr. Thomas Spanberger
Publikationsdatum
04.02.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00570-8